Rezolute (RZLT) Convertible Debt (2011 - 2018)
Rezolute recorded quarterly Convertible Debt of $5.0 million in Q4 2018, up 3.43% quarter-over-quarter from $4.8 million in Q3 2018.
Rezolute's Convertible Debt history runs 3 years deep, the most recent figure standing at $5.0 million for Q4 2018.
- In Q4 2018, Convertible Debt changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2018 stood at $5.0 million (changed N/A YoY), while the FY2011 annual figure was $54958.0, changed N/A from the prior year.
- Convertible Debt came in at $5.0 million for Q4 2018 at Rezolute, up from $4.8 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $5.0 million in Q4 2018 to a low of $4.8 million in Q3 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 5.01 Mn |
| Sep 30, 2018 | 4.84 Mn |
| Dec 31, 2013 | 2.70 Mn |
| Mar 31, 2013 | 3.73 Mn |
| Dec 31, 2011 | 54,958.00 |